in association with DM, IR and obesity, although the results are conflicting. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Studies regarding the association of Pro12Ala with atherosclerosis are scarce. A recent study by Ridker et al reported a reduced future incidence of myocardial infarction in healthy male carriers of Pro12Ala, 27 and Temelkova-Kurktschiev et al reported a protective influence of the Ala12Ala genotype on intima -media thickness in subjects at high risk for type 2 DM. 28 In contrast, Bluher et al reported the absence of any significant correlation of PPAR-2 polymorphisms, including Pro12Ala, with the occurrence of CAD in 365 diabetic patients, 29 and a recent study by Pischon et al could not find a correlation of Pro12Ala polymorphism with CAD. 30 There are no studies to date regarding the association of CAD with Pro12Ala polymorphism in Asian populations, so we performed genotyping analyses of Pro12Ala polymorphism in exon B of PPAR-in Korean subjects who underwent coronary angiography and analyzed its association with the presence or severity of CAD.
Methods

Patients
Of the total 1,308 cases of coronary angiography performed for the chief complaint of chest pain, at rest or under exertion, at the Cardiology Department in Kangbuk Samsung Medical Center, Seoul, Korea during May 2003 to August 2004, 267 subjects were enrolled after exclusion of those with problematic diseases or medication, repeat follow-up cases and cases of failed genotyping. Those with medical illnesses such as acute infection, chronic renal failure (serum creatinine ≥2.0 mg/dl), malignancies and other severe medical illnesses were excluded. The patients included 158 men and 109 women whose median age was 58.2±10.8 years (range 24-87 years). Written informed consent was given by each participant and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee
Anthropometric Measurements and Blood Chemistry
Height (cm), weight (kg), and systolic and diastolic blood pressures were measured in duplicate and the results were averaged. Body mass index (BMI) was calculated by dividing the weight by the square of height (m).
After 12 h of fasting, blood samples were taken for measurement of fasting blood glucose (FBG), total cholesterol, triglyceride, high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C). The hexokinase method was used to measure blood glucose levels and the enzymatic calorimetric test was used to measure total cholesterol and triglyceride levels. The selective inhibition method was used to measure the level of HDL-C and the homogeneous enzymatic colorimetric test was used to measure the level of LDL-C.
Coronary Artery Angiography
Coronary artery angiography was performed in all patients by trained cardiologists, who have been certified by the Korean Society of Circulation for at least 3 years. Significant stenosis was defined as a decrease in the internal diameter by more than 50%. Patients were grouped accord- ing to the number of significantly stenotic vessels: normal, 1-vessel, 2-vessel and 3-vessel disease.
Genotyping Using Real-Time Polymerase Chain Reaction
Buffy coat was obtained from blood samples, refrigerated at -70°C, and genomic DNA was extracted using Takara DNA Purification kits. The genotyping of Pro12Ala polymorphism in exon B of PPAR-was performed using an allelic discrimination assay using TaqMan probes.
The detector was an ABI Prism 7200 sequence detection platform (Perkin Elmer) and the primers and probes were as follows.
Primers Forward: TCC ATG CTG TTA TGG GTG AAA CT; Reverse: CTT TAC CTT GTG ATA TGT TTG CAG ACA.
Probes 5' FAM-TCT CCT ATT GAC CCA GAA AGC GAT TCC TT3' 5'VIC-TCT CCT ATT GAC GCA GAA AGC GAT TCC TT 3'
Statistical Analysis
All results are expressed as mean ± SD and significance was defined as p<0.05. Analysis was done using SPSS version 12.0 (Chicago, IL, USA). The Hardy-Weinberg equilibrium test was performed using the chi-square test. Comparisons of the cardiovascular risk factors among the different groups categorized by the severity of CAD were performed with ANOVA test, and the ANCOVA test was used to compare the mean values between groups after adjustment for age and BMI. Student's t-test was used to compare the mean values between different genotype groups and the chi-square test analyzed the association of the polymorphism with the presence of metabolic syndrome, DM and CAD. Logistic regression analysis was performed to determine the predictor of CAD after adjustment for confounding variables.
Results
Among the 267 subjects, 243 (91.0%) had the Pro12Pro genotype, 24 (9.0%) had the Pro12Ala genotype, and none had Ala12Ala. The allele frequencies were 0.955 for praline and 0.045 for alanine, which was in compliance with the Hardy-Weinberg equilibrium (p=0.74).
Clinical Characteristics
The mean age of the population was 58.2±10.8 years, and the mean BMI and FBG was 25.5±2.8 kg/m 2 and 6.4± 2.1 nmol/L, respectively (Table 1) . 125 subjects (46.8%) satisfied the diagnostic criteria for metabolic syndrome by ATP III guideline, and the number of subjects with DM was 82 (30.7%). 31 Among the total subjects, 117 (43.8%) had normal coronary arteries, 88 (33%) had 1-vessel disease, 39 (14.6%) had 2-vessel disease and 23 had (8.6%) 3-vessel disease ( Table 1) .
Comparison of Cardiovascular Risk Factors According to Severity of CAD
Mean values for the various risk factors were compared according to the number of stenotic vessels ( Table 2) . Subjects in the 3-vessel group were the oldest. The mean FBG level was the lowest in subjects with normal coronary arteries and showed significant differences between the groups, which were significant even after adjustment for age and BMI ( Comparison of Cardiovascular Risk Factors According to Pro12Ala Polymorphisms in PPAR-When the mean values of the cardiovascular risk factors were compared according to Pro12Ala polymorphism, there were no significant differences between the Pro12Pro and Pro12Ala genotypes in age, BMI, blood pressures, FBG or lipid profiles (Table 3 ).
There were no significant associations between the Pro12Ala genotypes and the presence of metabolic syndrome or DM ( Table 4 ).
Association of Pro12Ala Polymorphism With the Presence and Severity of CAD
The relationship of CAD with the genotypes of Pro12Ala was analyzed ( Table 5 ). In the Pro12Pro genotype group, 136 subjects (56.0%) had significant stenotic coronary arteries and 14 (58.3%) in the Pro12Ala genotype group had significant stenotic coronary arteries, although it was not statistically significant (p=0.824). Furthermore, there were no differences in the proportion of subjects with the different numbers of stenotic vessels according to genotype group (p=0.394).
Logistic Regression Analysis With CAD as the Dependent Variable
To determine the predictor for CAD, logistic regression analysis was performed with CAD as the dependent variable (Table 6 ). Age, sex and BMI were significant predictors for CAD, but Pro12Ala polymorphism was not, as expected (Table 6 ).
Discussion
In this study, none of the Korean subjects had the Ala12Ala genotype. In previous studies performed in other populations, including Koreans, the Ala12Ala genotype was rarely detected, with an allele frequency of 0.03-0.05. 26, 31, 32 Similar results were observed in other studies performed in other Asian populations, with rare frequency of the Ala12Ala genotype. 33, 34 In the present study the allele frequency of alanine was 0.043, similar to the previous studies.
The exact association of PPAR-polymorphism with CAD risk is not precisely clarified yet. The most studied PPAR-polymorphism in association with atherosclerosis is the C161T substitution in exon 6, which is a silent mutation. 4, 35, 36 Wang et al 36 reported a lower prevalence of CAD in carriers of C161T exon 6 compared with those without the polymorphism, suggesting the possibility of PPARpolymorphism in the pathogenesis of atherosclerosis. 36 Further results from Peng et al 4 were in line with the previous study, reporting a reduced CAD risk in those with C161T polymorphism in exon 6 of PPAR-.
Although a number of studies have been performed regarding the association between Pro12Ala polymorphism in exon B of PPAR-and IR, DM and obesity, the results are conflicting and no associations were seen in the present study. Previous association studies between Pro12Ala and CAD have failed to show consistent results either. Ridker et al analyzed Pro12Ala polymorphisms in 523 patients with myocardial infarction and in 2,092 control subjects who participated in the Physicians' Health Study, and found that subjects with the Ala allele had a 30% lower incidence of myocardial infarction. 27 Furthermore, Temelkova-Kurktschiev et al reported in their analyses of 622 participants in the RIAD (Risk factors in Impaired glucose tolerance for Atherosclerosis and Diabetes) study, that those with the Ala12Ala genotype showed a significantly reduced intimamedia thickness of the carotid artery compared with those with the other 2 genotypes, suggesting a protective effect of Pro12Ala polymorphism in the early phase of atherosclerosis. 28 In contrast, Bluher et al analyzed PPAR-2 polymorphisms in diabetic patients, and found no significant association with the presence of CAD. 29 A recent study by Pischon et al reported that in the 6-year follow-up study of American participants in the Nurses' Health Study and Health Professionals Follow-Up Study, those with the Ala allele had a significantly increased risk for CAD, and that these results were more significant in obese subjects, suggesting that the involvement of Pro12Ala polymorphism in the vasculature could occur in association with obesity. 30 In the present study, no significant association was observed between Pro12Ala PPAR-and the presence of CAD in Korean subjects. Furthermore, no differences were seen in the comparison analyses between the genotype groups in the mean values for cardiovascular risk factors such as age, BMI, blood pressure, FBG and lipid profiles. These results suggest a low possibility of involvement of Pro12Ala PPAR-polymorphism in the occurrence and risk for CAD in this study population. The reason for the discrepancy between this and the previous studies can be explained in several ways. First, the other studies were performed mostly in Caucasians, so the results cannot be compared with those from studies performed in Asians, because the Ala allele is too rarely observed in the latter population. Because the Ala allele was associated with a 30% lower incidence of CAD and the Ala12Ala genotype carriers showed a reduced intima-media thickness in previously reported studies, 27, 28 the scarcity of the Ala allele in the Asian population could have influenced the discrepancy of CAD incidence between the Asian and Caucasian populations. In addition, ethnic differences in nutrient excess could be a factor that affected the results. Second, the present study population is relatively small, thus the result could have low statistical power. Third, this study was not prospective and therefore we are unable to draw a definite conclusion. Nonetheless, this study is meaningful in that coronary angiography was performed in all participants, and we attempted to analyze the association between polymorphism and disease severity in a relatively novel ethnic group.
In summary, this study revealed that Pro12Ala polymorphism in exon B of PPAR-showed no significant association with the presence of CAD or cardiovascular risk factors in a Korean population. This study has additional strength in that the coronary artery status was confirmed and the analyses were performed with a documented number of stenotic vessels. Further studies of this polymorphism and CAD are warranted in a larger number of Asian study subjects.
